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A B S T R A C T
Purpose: To assess the utility of retigabine (RTG) for epilepsy in clinical practice at a single UK tertiary
centre.
Methods: We identiﬁed all individuals who were offered RTG from April 2011 to May 2013. We collected
demographics, seizure types, previous and current antiepileptic drugs (AEDs), starting and maximum
attained daily dose of RTG, clinical beneﬁts, side effects, and reason to discontinue RTG from in- and
outpatient encounters until February 28, 2014.
Results: 145 people who had failed a median of 11 AEDs took at least one dose of RTG. One year retention
was 32% and decreased following the safety alert by the US Federal Drug Administration (FDA) in April
2013. None became seizure free. 34 people (24%) reported a beneﬁt that was ongoing at last assessment
in ﬁve (3%). The most relevant beneﬁt was the signiﬁcant reduction or cessation of drop attacks or
seizure-related falls in four women, this persisted at last assessment in two. The presence of simple
partial seizures was associated with longer retention, as was a higher attained dose of RTG. Adverse
effects were seen in 74% and largely CNS-related or nonspeciﬁc and affected the genitourinary system in
13%.
Conclusion: Retention of RTG was less favourable compared to data from open label extension studies of
the regulatory trials. In comparison with historical data on similar retention audits retention of RTG at
one year appears to be less than lamotrigine, topiramate, levetiracetam, pregabalin, zonisamide, and
lacosamide, and slightly higher than gabapentin.
 2014 The Authors. ISDN. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Retigabine (RTG) is a ﬁrst-in-class AED that reduces neuronal
excitability by enhancing neuronal potassium channel activity. It was
licensed in the EU and became available in the UK in 2011. Its efﬁcacyAbbreviations: AED, antiepileptic drug; FDA, Federal Drug Administration of the US;
GBT, gabapentin; LCM, lacosamide; LTG, lamotrigine; LEV, levetiracetam; PGB,
pregabalin; RTG, retigabine; SUDE, sudden unexplained death in epilepsy; TPM,
topiramate; ZNS, zonisamide.
* Corresponding author at: National Hospital for Neurology and Neurosurgery,
Box 141, 23 Queen Square, London WC1N 3BG, United Kingdom.
Tel.: +44 20 3448 3287.
E-mail addresses: tim.wehner@uclh.nhs.uk, m.wehner@uclh.nhs.uk
(T. Wehner), dr.chinnasami.suganthi@gmail.com (S. Chinnasami),
jan.novy@chuv.ch (J. Novy), gail.bell@ucl.ac.uk (G.S. Bell), j.duncan@ucl.ac.uk
(J.S. Duncan), l.sander@ucl.ac.uk (J.W. Sander).
http://dx.doi.org/10.1016/j.seizure.2014.08.001
1059-1311/ 2014 The Authors. ISDN. Published by Elsevier Ltd. This is an open accesas an add-on medication in people with focal epilepsy was shown in
three regulatory randomised controlled trials that assessed daily
doses of 600, 900 and 1200 mg, lasting up to 18 weeks.1–3
Results of regulatory trials do not necessarily translate well into
clinical practice. Many people with pharmacoresistant epilepsy
may not meet inclusion criteria for a trial, and a follow-up period of
18 weeks does not inform about efﬁcacy and tolerability in a
clinically more relevant longer time frame. At our centre, we have
assessed the retention, efﬁcacy and tolerability of novel AEDs over
the past 15 years in large cohorts of people with pharmacoresistant
epilepsy.4–8 In April 2013, the FDA issued a safety warning about
RTG following reports about retinal pigmentation and blue
discoloration of skin and nails in people exposed to the medication
in open label extension studies.9
We present retention data for RTG from our centre before and
after the FDA warning.s article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Table 1
Patient demographics.
Demographic data (n = 145) Number Percentage
Age when starting RTG 42.0 (median) 17–66 (range)
Gender (female) 84 57.9%
Age at epilepsy onset 13 (median) First year of
life–48 (range)
Learning disabilities 28 19.3%
Psychiatric history 54 37.2%
Focal epilepsy 137 94.5%
Symptomatic 83 57.2%
Cryptogenic 54 37.2%
Generalised epilepsy 6 4.1%
Symptomatic 2 1.4%
Cryptogenic 2 1.4%
Idiopathic 2 1.4%
Unclassiﬁed 2 1.4%
Number of concomitant AEDs
None 1 0.7%
One 20 13.8%
Two 54 37.2%
Three 36 24.8%
Four or more 34 23.4%
Number of AEDs previously tried
(excluding current AEDs)
9 (median) 1–17 (range)
Tried 6 AEDs or more previously 109 75.2%
RTG starting daily dose
50 mg 61 42.1%
100 mg 10 6.9%
150 mg 63 43.4%
200 mg or more 11 7.6%
Maximal dose of RTG 450 mg (median) 50–1500 mg
(range)
Attained dose of 600 mg or higher 65 44.8%
Disposition
Continuing at last follow-up 11 7.6%
Stopped 134 92.4%
Stopped because of side effects 55 41.0%
Stopped because of
inefﬁcacy/worsening
36 26.9%
Stopped because of side
effects & inefﬁcacy/worsening
23 17.2%
Stopped because of FDA alert 20 14.9%
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All people advised to start taking RTG between April 2011 and
May 2013, at the specialised epilepsy clinics of University College
London Hospitals, were identiﬁed through pharmacy records and
notes review. Exclusion criteria comprised RTG started for reasons
other than epilepsy, people who did not start it and, to avoid
survival bias, people who had RTG started elsewhere and those
who had taken part in a clinical trial of RTG. All but one participant
(who had failed and subsequently discontinued six AEDs) started
RTG as add-on treatment.
People were followed from the day that RTG was initiated. Data
on starting dose, highest exposed daily dose, efﬁcacy and side
effects were collected from computerised and paper records of
outpatient visits and hospital admissions. We recorded age at
starting RTG, age at seizure onset, current seizure types (ILAE
classiﬁcation), history of learning disability, psychiatric comorbid-
ity, and current and previous AED use. At each subsequent clinic
visit or telephone encounter, efﬁcacy was assessed as seizure
freedom, at least 50% improvement, marked improvement, no
change, or worsening of seizures. Side effects were recorded and
categorised according to body system affected. The reason for
stopping RTG was captured. The study was approved as an audit by
the hospital’s research ethics committee.
Statistical analysis was performed using Stata v13. The
retention rate of RTG was estimated using Kaplan–Meier survival
analysis, and effects of different factors were examined using Cox
regression analysis.
3. Results
The ﬁrst person was enrolled in April 2011, and the last one in
May 2013. The database was locked at the end of February 2014.
We identiﬁed 158 people who had been offered RTG (i.e. a
prescription was issued or they were started as inpatients). For 13 of
these, there was no evidence in subsequent records that they ever
started the medication. We systematically audited all outpatients
seen in our clinics over a two-week period in March 2012 (n = 330) to
assess the efﬁcacy of our enrolment strategy. All nine people who
were ﬂagged as starting on RTG were identiﬁed, suggesting that we
missed very few, if any, people exposed to the medication.
The analysis thus includes 145 people followed for 0–2.6 years
(mean 0.75 years, median 0.60 years); one stopped the drug on the
day it was started. Demographic data are summarised in the table
(Table 1).
As of February 28, 2014, six people (4%) were still on RTG. Three
people (2%) had been lost to follow-up and two had died (one from
SUDEP, one cause unknown; all while still on RTG).
Using survival analysis, estimated retention at one year was
30% (95% CI 22.6, 37.7%, Fig. 1). Altogether 11 people were
continuing with RTG at last follow-up although two of these had
been advised to withdraw it due to the FDA alert. Of the 134 who
stopped, 82 (61%) did so prior to 26th April 2013 (date of FDA
alert).9 One person started RTG after the FDA warning.
One person with daily seizures at baseline became seizure free
for three weeks. Thirty-four people (23%) had a period of 50%
reduction in seizure frequency or of patient-reported ‘marked
improvement’. Of 26 people with marked improvement, three (9%)
had marked improvement (nine to 27 months) at last follow-up.
Twenty-three people had a period of transient marked improve-
ment for between one and 28 months (mean 8.8 months, median
six months). Of nine people with a 50% reduction in seizure
frequency, two still had a 50% reduction at last follow-up. One of
the seven who did not have 50% seizure reduction at last follow-up
did; however, still report marked improvement for the previous
seven months at last follow-up.The maximum dose attained was associated with retention,
with those who achieved higher doses having longer retention. The
presence of simple partial seizures was also associated with
retention (HR 0.59, 95% CI 0.42–0.85) compared with those
without simple partial seizures. Additionally age at starting RTG
(HR 1.02, 95% CI 1.00, 1.04) affected retention.
We found no other demographic or clinical variable to affect
RTG retention (survival analysis). Speciﬁcally, gender (HR 0.80),
age at onset of epilepsy (HR 1.02), having generalised epilepsy
(compared with focal onset; HR 1.29), number of past AEDs tried
(compared with 1–6 previous AEDs, HR 1.01 for 7 or 8 previous
AEDs, 1.04 for 9 or 10 previous AEDs, and 1.08 for 11 or more
previous AEDs), number of concomitant AEDs (3 or more compared
with 2 or fewer; HR 0.94), starting dose of RTG (>100 mg daily
compared with 100 mg daily or less, HR 0.72), or seizure types
(with the exception of simple partial seizures) did not affect
retention. In multivariable analysis including those variables with
p < 0.2 in univariable analysis (with the exception of absence
seizures, experienced by only ﬁve people), the variables ‘‘maxi-
mum dose attained’’ and ‘‘presence of simple partial seizures’’
remained signiﬁcant. Compared with those with a maximum doses
of 300 mg or less, the HR was 0.46 (95% CI 0.28, 0.74) for those
taking 350–450 mg/day, was 0.44 (95% CI 0.28, 0.71) for those
taking 500–600 mg/day, and was 0.21 (95% CI 0.13, 0.37) for those
taking at least 700 mg/day. The HR for those with simple partial
seizures (compared with those who did not have simple partial
seizures) was 0.70 (95% CI 0.49, 0.997). The FDA warning from April
Fig. 1. Retention of RTG as Kaplan–Meier plot. Fig. 2. Retention of RTG compared to historical retention data using similar methods
on gabapentin (GBT),4 lamotrigine (LTG),4 lacosamide (LTG),8 levetiracetam (LEV),5
pregabalin (PGB),6 topiramate (TPM),4 and zonisamide (ZNS).7 Figure in part
reproduced from Novy et al., 2013.8
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still on the drug at this point, and there was a signiﬁcant difference
in retention before and after the warning (log rank test p = 0.0001).
One year retention was 31.9% (95% CI 22.3, 41.8%) before the
warning and 8.1% (95% CI 1.4, 22.7%) thereafter.
4. Notable individual beneﬁts
A 35-year-old woman with daily seizures and weekly seizure-
related falls reported complete cessation of drop attacks after
starting RTG for 32 months at last follow-up. A 19-year-old woman
with daily drop attacks at baseline experienced a marked reduction
of these for 9 months, when she was lost to follow-up.
Two more women reported transient complete or almost
complete cessation of drop attacks for 8 and 9 months, but drop
attacks returned at the previous frequency thereafter.
One woman became unintentionally pregnant on RTG (in
combination with levetiracetam and lacosamide). She and the
foetus are doing well at last follow-up 5 months into the
pregnancy.
5. Adverse effects
Adverse effects were experienced by 107 people (74%). Twenty-
four (17%) reported increase of their seizure frequency or intensity.
Somatic side effects were observed in 100 people (69%) after
starting RTG, and 17 people (13%) experienced psychiatric side
effects.
The most common side effects reported were attributed to the
CNS (cognitive slowing, double vision, speech disturbance etc.,
n = 55, 38%) or nonspeciﬁc (fatigue, weight gain; n = 54, 37%).
Problems with urination (urinary retention, dysuria, or inconti-
nence) were seen in 13 people (9%), a new skin rash in ﬁve (3%), lip
discoloration in one, and gastrointestinal problems in ﬁve (3%).
6. Discussion
Retention at one year was less favourable in this cohort (30%)
compared with data from both the open label extension studies of
two licensing studies (60%),10 and historical data from our centre
on retention of lamotrigine (46%),4 topiramate (52%),4 levetirace-
tam (75%),5 pregabalin (52%),6 zonisamide (62%),7 and lacosamide
(62%),8 and slightly better than gabapentin (23%, Fig. 2).4 Nobody
on RTG in this assessment achieved seizure freedom for at least sixmonths, compared to 13% in the open label extension studies,10
and transient or terminal six month seizure freedom rates of 2
(lamotrigine)–11% (levetiracetam) in our previous retention audits
mentioned.4–8 Differences in the study populations may explain
why retention and 50% responder rate were lower in this cohort
than in the regulatory trials and their open label extension
studies.10,11 People could participate in the regulatory trials if they
had ongoing seizures despite being on one to three AEDs.1–3 People
in the current cohort had failed a median of nine AEDs (excluding
current AEDs) and can thus be considered highly pharmacoresis-
tant. Nearly half of the people (48%) took RTG in addition to three
or more AEDs, compared to 24–31% in the RTG treatment arms in
the regulatory trials.1–3 This may explain the relatively low median
dose of RTG (450 mg) achieved by people in this cohort, and, in
turn, the much lower 50% responder rates compared to the
regulatory trials and open label extension studies.1–3,10,11 In fact,
only 45% of people reached a dose of 600 mg or above, which has
been postulated the minimum effective dose in the regulatory
trials.1–3,11
People who attained higher doses had longer retention. This
may be that those who attained higher doses had better efﬁcacy
and therefore continued to take RTG longer; alternatively that
those who tolerated RTG sufﬁciently well to continue to take it
therefore reached higher doses. It is unclear why people with
simple partial seizures had longer retention than those without. In
our previous assessments, we did not ﬁnd any correlation (positive
or negative) of retention rates and seizure types.
The clinically most relevant beneﬁt observed in this cohort was
cessation or marked reduction in drop attacks or seizure-related
falls in four people. To the best of our knowledge, this has not been
reported before. Falls are not speciﬁc for a particular seizure type,12
and no current video EEG data were available to assess the
mechanism of seizure-related falls in these people. Therefore, it
remains unclear whether RTG affects a particular seizure type
leading to falls.
Adverse effects were broadly similar to those in regulatory trials
and their open label extension studies, in that they were either
nonspeciﬁc or linked to the CNS. Genitourinary side effects
(urinary retention, urinary incontinence, or dysuria) were reported
by 9% of people in this cohort compared with 12% in the open label
extension studies.10
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discontinuation. While our best efforts were made to capture the
reason for discontinuation, in clinical reality the decision to
discontinue an AED is most often likely due to a combination of
lack of efﬁcacy and actual or potential adverse effects. It is thus not
surprising that the FDA warning in April 2013 affected retention.
7. Conclusion
The presumed mechanism of action of RTG, reduction of neuronal
excitability through opening of potassium channels did not translate
into sustained beneﬁt in the majority of people with highly
refractory epilepsy in this cohort. Even prior to the FDA warning,
retention was unfavourable compared to historical controls on
lamotrigine, topiramate, levetiracetam, pregabalin, zonisamide, and
lacosamide. Nonetheless, our data suggest a potential beneﬁt in
some people with drop attacks or frequent seizure-related falls.
Further research is suggested to investigate this effect.
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